Pharmaceutical Company
Issues generally related to the Orphan Drug Tax Credit. Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives; drug pricing proposals; access to rare disease and gene therapy drugs, including S. 2543, The Prescription Drug Pricing Reduction Act of 2019, H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 19, the Lower Costs, More Cures Act of 2019, H.R. 5882, the GENE Therapy Payment Act, and H.R. 4439, Creating Hope Reauthorization Act; newborn screening and gene panel screening, including, H.R. 2507, the Newborn Screening Saves Lives Reauthorization Act of 2019 and S. 2158, the Newborn Screening Saves Lives Reauthorization Act of 2019; H.R. 4439, Creating Hope Reauthorization Act; and FDA approvals of drugs designed to treat rare diseases; Health care policies in P.L. 116- 123, the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; P.L. 116-127, the Families First Coronavirus Response Act; P.L. 116-136, the Coronavirus Aid, Relief, and Economic Security Act of CARES Act; P.L. 116-139, the Paycheck Protection Program and Health Care Enhancement Act; H.R. 6800, the Heroes Act; H.R. 8406, the Heroes Act; Senate Amendment 2652 related to COVID-19 relief; P.L. 116-159, the Continuing Appropriations Act, 2021 and Other Extensions Act; and P.L.116-260, Consolidated Appropriations Act, 2021. Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, and access to rare disease and gene therapy drugs. Policies proposed in 85 FR 37286, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 4225, For the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, Karla Maria Barrera De Bueso, and Ana Lucia Bueso Barrera, and S. 2612, For the relief of Maria Isabel Bueso Barrera, Alberto Bueso Mendoza, Karla Maria Barrera De Bueso, and Ana Lucia Bueso Barrera.
TAX - Taxation/Internal Revenue Code HCR - Health Issues MMM - Medicare/Medicaid IMM - Immigration
136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CHAMBER HILL STRATEGIES
3325 N Kensington Street, Arlington, VA, 22207, US
MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN
Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce